Polo-like kinase 1 (PLK1) has gained recognition as a promising therapeutic target in oncology due to its critical role in cell cycle control and mitotic progression. With increasing scientific validation and a growing understanding of tumor biology, the PLK1 inhibitor Market is attracting attention from both established pharmaceutical players and innovative biotech firms seeking to translate...